Background: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate therapy for these patients. Methodology/Principal Findings: In order to guarantee the possibility for mCRC patients to receive an high quality KRAS testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology -Italian division of the International Academy of Pathology (SIAPEC-IAP) started a program to improve KRAS testing. AIOM and SIAPEC identified a large panel of Italia...
Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial pre...
International audiencePURPOSE: Rapid advances in the understanding of cancer biology have transforme...
International audienceBACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-e...
BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have ...
Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approve...
Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...
Metastatic colorectal cancer harboring a mutation in codon 12 or 13 of the KRAS gene does not benef...
KRAS testing is relevant for the choice of the most appropriate first-line therapy of metastatic col...
Abstract KRAS testing is relevant for the choice of the most appropriate first-line therapy of meta...
The use of epidermal growth factor receptor-targeting antibodies in metastatic colorectal cancer has...
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcome...
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growt...
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcome...
The presence of mutations in the KRAS gene is a predictor of a poor clinical response to EGFR-target...
In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type ...
Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial pre...
International audiencePURPOSE: Rapid advances in the understanding of cancer biology have transforme...
International audienceBACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-e...
BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have ...
Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approve...
Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...
Metastatic colorectal cancer harboring a mutation in codon 12 or 13 of the KRAS gene does not benef...
KRAS testing is relevant for the choice of the most appropriate first-line therapy of metastatic col...
Abstract KRAS testing is relevant for the choice of the most appropriate first-line therapy of meta...
The use of epidermal growth factor receptor-targeting antibodies in metastatic colorectal cancer has...
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcome...
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growt...
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcome...
The presence of mutations in the KRAS gene is a predictor of a poor clinical response to EGFR-target...
In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type ...
Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial pre...
International audiencePURPOSE: Rapid advances in the understanding of cancer biology have transforme...
International audienceBACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-e...